NGS Assay Development
This guide contains best practices to help you develop an NGS-based clinical genomics assay and bring it online quickly and cost-effectively. It discusses specific ways to overcome the top three assay development challenges faced by clinical laboratories.
NGS assay implementation can be extremely costly, even more so if you don’t follow best practices. Learn how highly multiplexed NGS reference materials can help you speed development, validate more robustly, and implement better clinical genomics assays.
NGS Assay Validation and QC
A practical guide focuses on the validation process for NGS-based assays and will walk through key considerations and guidelines you can follow to ensure a smooth and successful validation.
A protocol, developed in partnership with Thermo Fisher Scientific, that ensures a thorough and accurate assessment of your Ion Torrent Oncomine Myeloid Research Assay prior to routine deployment using the Seraseq Myeloid Reference Materials (RNA and DNA).
Whatever practices you use for NGS assay development, validation, and performance monitoring, your goal is the same: Your results must be as accurate, precise, and consistent as possible.
A technical explanation of our proprietary reference material technology that overcomes the problems of low library yield and low library complexity that using sheared cell-line DNA presents.
This white paper details the panel at the 2017 Precision Medicine World Conference (PMWC), "Achieving Accurate NGS Test Results." Panelists discuss achieving high levels of accuracy with NGS, giving key insights and an in-depth look at specifics that contribute to variability.
Save time and money collecting and organizing QC data for audits and troubleshooting. Francine de Abreu, PhD, discusses several ways in which using automated QC tracking software is critical for high-throughput validation and routine clinical use.
AccuPlex Technology for Rapid Development of Molecular Diagnostic Assays in Response to Viral Infectious Diseases
This white paper details how AccuPlexTM recombinant virus technology enables replication-defective virus particles that are commutable in any sample matrix and closely mimic pathogenic virus found in clinical samples.
Comparison of the KPL BacTrace Anti-Salmonella CSA-Plus Antibody to Two Other Anti‑Salmonella Species Antibodies in an Indirect ELISA
Learn why KPL BacTrace antibodies outperform both polyclonal and monoclonal antibodies in an indirect ELISA, and how we achieve the broad reactivity of a polyclonal antibody combined with the specificity of a monoclonal antibody.